KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $167.5 million.

  • Travere Therapeutics' Non-Current Assets fell 678.97% to $167.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $695.3 million, marking a year-over-year decrease of 295.34%. This contributed to the annual value of $177.4 million for FY2024, which is 307.02% up from last year.
  • Travere Therapeutics' Non-Current Assets amounted to $167.5 million in Q3 2025, which was down 678.97% from $175.7 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Non-Current Assets registered a high of $203.3 million during Q1 2023, and its lowest value of $146.6 million during Q3 2023.
  • In the last 5 years, Travere Therapeutics' Non-Current Assets had a median value of $186.1 million in 2022 and averaged $184.7 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 2338.52% in 2023, then soared by 2254.13% in 2024.
  • Travere Therapeutics' Non-Current Assets (Quarter) stood at $193.8 million in 2021, then fell by 3.95% to $186.1 million in 2022, then dropped by 7.53% to $172.1 million in 2023, then rose by 3.07% to $177.4 million in 2024, then dropped by 5.61% to $167.5 million in 2025.
  • Its last three reported values are $167.5 million in Q3 2025, $175.7 million for Q2 2025, and $174.6 million during Q1 2025.